| Name | Title | Contact Details |
|---|
Environmental Infection Control Consultants (EICC) is a Chalfont, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Compassus is a national leader in providing high-quality, compassionate, person-centered care to individuals wherever they call home. Our continuum of integrated home-based care, including home health infusion therapy palliative and hospice care ensures patients and their families have the support they need to address current and future health needs. Partnering with Compassus brings peace of mind to patients, caregivers, and health care providers. Our team members work collaboratively to manage patient conditions and meet goals of care alongside referring physicians, health systems, long-term care partners, and family members. Our value is in the compassion and expertise of our teams, which act as an extension of patients` existing care teams. We believe everyone who interacts with us should experience our individualized `Care for who` I am philosophy, from the care services we provide to patients and families to how we interact with our partners and one another.
The b.well connected health platform provides an all-in-one integrated solution for consumer engagement, holistic health management, and cost containment. Our use of longitudinal aggregated data creates a complete picture of health for each consumer and is aggregated to allow for true population health management. Our unique approach to partner integration allows our customers to change their programs in real time as the health needs of their population change, not on an annual sales cycle. With the b.well platform there is one contract, one implementation and the elimination of point-solution fatigue. We provide real-time transparent dashboards to all customers highlighting return on investment, cost containment opportunities, engagement metrics and outreach campaign outcomes, clinical risk factors and disease states. b.well supports health plans, health systems, employers and pharmaceutical companies to bring their digital strategy to life and enables them to provide their employees, members and patients with the one thing they do not have today; one place to manage all aspects of their health.
Discovery Laboratories, Inc. is a specialty biotechnology company focused on advancing a new standard in respiratory critical care. Discovery Labs` technology platform includes its novel proprietary KL4 surfactant, a synthetic, peptide-containing surfactant that is structurally similar to pulmonary surfactant, and its proprietary drug delivery technologies being developed to enable efficient delivery of aerosolized KL4 surfactant and other inhaled therapies. Discovery Labs` strategy is initially focused on neonatology and improving the management of respiratory distress syndrome (RDS) in premature infants. Discovery Labs believes that its RDS product portfolio has the potential to become the new standard of care for RDS and, over time, enable the treatment of a significantly greater number of premature infants who could benefit from surfactant therapy that are currently not being treated. In many pulmonary diseases, including RDS, acute lung injury (ALI), and other respiratory conditions, surfactant is either deficient or may fail to function properly. Our precision-engineered, peptide-containing KL4 surfactant has been designed to mimic the essential function of human pulmonary surfactant and may have the potential to address conditions such as these. We are developing our proprietary delivery technologies to one day enable efficient, targeted upper-respiratory or alveolar delivery of our KL4 surfactant in aerosolized form to allow for a gentler, less invasive delivery approach. These same delivery systems may also potentially be used to deliver a variety of additional aerosolized medicines safely and in a simplified way compared with the current standard of care.
INTEGRIS Health is Oklahoma's largest privately owned health system.